ReviewFrontiers in microbiology2022
Regulation of
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Genetic control of Group 3 (K96) capsule synthesis and complement resistance in extraintestinal pathogenicmSphere · 2026Article
- Virulence Gene Profiles of Extended-Spectrum β-Lactamase (ESBL)-ProducingVeterinary sciences · 2025Article
- Genome-wide mapping of cyclic AMP receptor protein binding in EnteroaggregativebioRxiv : the preprint server for biology · 2025Article
- Genome-wide mapping of cAMP receptor protein binding in enteroaggregativeMicrobiology (Reading, England) · 2025Article
- Mechanisms governing bacterial capsular polysaccharide attachment and chain length.Annals of the New York Academy of Sciences · 2025Review
- RyhB Regulates Capsular Synthesis for Serum Resistance and Virulence of Avian PathogenicInternational journal of molecular sciences · 2025Article
- Role for RTX-family toxin HlyA of extraintestinal pathogenicFEMS microbes · 2025Article
- Article
- Article
- Synergy between Group 2 capsules and lipopolysaccharide underpins serum resistance in extra-intestinal pathogenicMicrobiology (Reading, England) · 2024Article
- Whole-Genome Sequencing of Human and PorcineAntibiotics (Basel, Switzerland) · 2024Article
- Integrating Genomic Data with the Development of CRISPR-Based Point-of-Care-Testing for Bacterial Infections.Current clinical microbiology reports · 2024Review
- Identification of genes influencing the evolution ofMicrobial genomics · 2023Article
- Article
- Klebsiella pneumoniae l-Fucose Metabolism Promotes Gastrointestinal Colonization and Modulates Its Virulence Determinants.Infection and immunity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of a group 2 capsule (K antigen), such as the K1 or K5 antigen, is a key virulence factor of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.